Northern Trust Corp Prothena Corp Public LTD CO Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Northern Trust Corp holds 372,655 shares of PRTA stock, worth $4.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
372,655
Previous 364,106 2.35%
Holding current value
$4.86 Million
Previous $7.52 Million 17.05%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$16.73 - $24.79 $143,024 - $211,929
8,549 Added 2.35%
372,655 $6.23 Million
Q2 2024

Aug 14, 2024
SELL
$19.54 - $26.15 $647,887 - $867,055
-33,157 Reduced 8.35%
364,106 $7.52 Million
Q1 2024

May 14, 2024
SELL
$24.75 - $40.66 $169,463 - $278,399
-6,847 Reduced 1.69%
397,263 $9.84 Million
Q4 2023

Feb 13, 2024
SELL
$32.31 - $52.32 $185,362 - $300,159
-5,737 Reduced 1.4%
404,110 $14.7 Million
Q3 2023

Nov 13, 2023
SELL
$47.3 - $70.6 $100,654 - $150,236
-2,128 Reduced 0.52%
409,847 $19.8 Million
Q2 2023

Aug 11, 2023
BUY
$48.26 - $78.59 $1.41 Million - $2.3 Million
29,287 Added 7.65%
411,975 $28.1 Million
Q1 2023

May 15, 2023
BUY
$46.97 - $58.27 $991,207 - $1.23 Million
21,103 Added 5.84%
382,688 $18.5 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $751,445 - $938,405
14,437 Added 4.16%
361,585 $21.8 Million
Q3 2022

Nov 14, 2022
SELL
$25.16 - $60.63 $127,636 - $307,575
-5,073 Reduced 1.44%
347,148 $21 Million
Q2 2022

Aug 12, 2022
SELL
$22.73 - $39.98 $285,738 - $502,588
-12,571 Reduced 3.45%
352,221 $9.56 Million
Q1 2022

May 13, 2022
SELL
$30.27 - $49.22 $2.42 Million - $3.94 Million
-80,027 Reduced 17.99%
364,792 $13.3 Million
Q4 2021

Feb 08, 2022
BUY
$42.11 - $73.26 $161,449 - $280,878
3,834 Added 0.87%
444,819 $22 Million
Q3 2021

Nov 15, 2021
SELL
$48.2 - $78.89 $14,411 - $23,588
-299 Reduced 0.07%
440,985 $31.4 Million
Q2 2021

Aug 13, 2021
BUY
$21.63 - $57.65 $2.16 Million - $5.77 Million
100,009 Added 29.3%
441,284 $22.7 Million
Q1 2021

May 12, 2021
SELL
$11.0 - $28.24 $317,735 - $815,712
-28,885 Reduced 7.8%
341,275 $8.57 Million
Q4 2020

Feb 11, 2021
SELL
$10.12 - $13.94 $166,646 - $229,549
-16,467 Reduced 4.26%
370,160 $4.45 Million
Q3 2020

Nov 16, 2020
SELL
$9.93 - $13.47 $444,010 - $602,297
-44,714 Reduced 10.37%
386,627 $3.86 Million
Q2 2020

Aug 14, 2020
SELL
$9.56 - $12.51 $798,307 - $1.04 Million
-83,505 Reduced 16.22%
431,341 $4.51 Million
Q1 2020

May 14, 2020
SELL
$7.54 - $15.77 $150 - $315
-20 Reduced -0.0%
514,846 $5.51 Million
Q4 2019

Feb 14, 2020
BUY
$7.48 - $17.01 $155,703 - $354,080
20,816 Added 4.21%
514,866 $8.15 Million
Q3 2019

Nov 13, 2019
SELL
$6.89 - $10.45 $184,383 - $279,652
-26,761 Reduced 5.14%
494,050 $3.87 Million
Q2 2019

Aug 13, 2019
BUY
$8.85 - $12.49 $316,626 - $446,854
35,777 Added 7.38%
520,811 $5.5 Million
Q1 2019

May 13, 2019
SELL
$10.32 - $14.49 $11,248 - $15,794
-1,090 Reduced 0.22%
485,034 $5.88 Million
Q4 2018

Feb 12, 2019
SELL
$8.73 - $13.74 $79,757 - $125,528
-9,136 Reduced 1.84%
486,124 $5.01 Million
Q3 2018

Nov 14, 2018
BUY
$12.7 - $15.79 $457,428 - $568,724
36,018 Added 7.84%
495,260 $6.48 Million
Q2 2018

Sep 18, 2018
SELL
$10.99 - $44.21 $22,386 - $90,055
-2,037 Reduced 0.44%
459,242 $6.7 Million
Q2 2018

Aug 14, 2018
BUY
$10.99 - $44.21 $21,958 - $88,331
1,998 Added 0.44%
461,279 $6.73 Million
Q1 2018

May 09, 2018
BUY
$27.95 - $45.04 $83,374 - $134,354
2,983 Added 0.65%
459,281 $16.9 Million
Q4 2017

Feb 14, 2018
SELL
$35.44 - $63.76 $54,435 - $97,935
-1,536 Reduced 0.34%
456,298 $17.1 Million
Q3 2017

Nov 13, 2017
BUY
$53.83 - $67.75 $24.6 Million - $31 Million
457,834
457,834 $29.7 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $612M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email